Author

Sudeshna Datta

Institute of Life SciencesORCID 0000-0003-0470-9079Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Sudeshna Datta1 paper · National Institute of Immunology

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Genetic & Genomic Medicine· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Approach:statistical model· 1 Research Focus:variant calling· 1 Assay:whole-exome sequencing· 1

Frequent Co-Authors

Mamuni Swain· 2 shared Sunil K. RaghaviD· 2 shared Analabha BasuiD· 1 shared Arup GhoshiD· 1 shared Bhawna GuptaiD· 1 shared Deepak Jena· 1 shared Dillip Kumar MudulyiD· 1 shared Pallavi MohapatraiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersGenetic & Genomic Medicine

Mamuni Swain

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Genetic & Genomic MedicinemedRxivPreprintJan 13, 2026

Fine-scale genetic structure and population-specific clinically relevant variants in the indigenous tribal populations of India

Sudeshna Datta, Deepak Jena, Arup Ghosh…·Sunil K. Raghav

The paper analyzes whole-exome sequencing data from 13 tribal groups in Odisha, India, identifying genetic structure, rare variants, and clinically relevant pathogenic variants.

2 citations

humanwhole-exome sequencing

Cancer BiologyBritish Journal of CancerPeer-reviewedSep 9, 2025

NEK9 ablation rewires docetaxel resistance through induction of ERK-mediated cancer cell pyroptosis

Shamima Azma Ansari, Sibasish Mohanty, Pallavi Mohapatra…·Rupesh Dash

This study identifies NEK9 as a driver of docetaxel resistance in cancers and shows that its ablation sensitizes cells to docetaxel via ERK-mediated pyroptosis, suggesting fostamatinib as a potential therapeutic partner.

3 citations

humanexperimental assay